Related Experiment Video

Updated: Apr 18, 2026

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening
06:50

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening

Published on: September 5, 2025

623

Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance

Si-Han Wu1, Jun-Feng Bi1, Timothy Cloughesy1

  • 11 Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, CA 92093, USA ; 2 Neuro-Oncology Program, University of California, Los Angeles, CA 90095, USA.

Cancer Biology & Medicine
|January 23, 2015
PubMed

Insights

Mechanistic target of rapamycin complex 2 (mTORC2) plays a key role in glioblastoma (GBM) growth and treatment resistance. Targeting mTORC2 presents a promising new strategy for treating this lethal brain cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Glioblastoma (GBM) is a highly aggressive and lethal primary brain tumor.
  • Genomic studies reveal mechanistic target of rapamycin (mTOR) signaling is crucial in GBM pathogenesis.
  • mTOR functions via two complexes, mTORC1 and mTORC2, with distinct roles and drug sensitivities.

Purpose of the Study:

  • To review current research on the role of mTORC2 in glioblastoma.
  • To highlight mTORC2's involvement in GBM tumor progression and therapeutic resistance.
  • To establish mTORC2 as a potential therapeutic target for GBM.

Main Methods:

  • Literature review of recent findings on mTORC2 in GBM.
  • Analysis of studies investigating mTORC2's impact on tumor growth and metabolism.
  • Examination of research on mTORC2's role in resistance to targeted therapies.

Main Results:

  • mTORC2 significantly regulates GBM tumor growth and progression.
  • mTORC2 is implicated in metabolic reprogramming within GBM cells.
  • mTORC2 signaling contributes to resistance against current GBM therapies.

Conclusions:

  • mTORC2 is a critical regulator of key oncogenic processes in glioblastoma.
  • Targeting mTORC2 offers a promising therapeutic avenue for GBM treatment.
  • Further investigation into mTORC2 inhibitors is warranted for GBM clinical application.
Keywords:
GlioblastomaPI3KWarburg effectmTORmTORC2metabolic reprogramming

More Related Videos

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

6.1K
Laboratory-Engineered Glioblastoma Organoid Culture and Drug Screening10:49

Laboratory-Engineered Glioblastoma Organoid Culture and Drug Screening

Published on: January 10, 2025

1.6K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K